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5-Fluorouracil (5-FU) has been widely used as an anti-cancer drug
for more than three decades (Grem, 1996). Its clinical application
was further expanded by the introduction of an innovative HDFL
regimen in which high-dose 5-FU (2600 mg m–2 week–1) and
leucovorin (500 mg m–2 week–1) were administered by weekly
24-h infusion (Ardalan et al, 1991). We and others have demon-
strated that HDFL, alone or in combination with other anti-cancer
drugs, is an effective regimen in the treatment of colorectal cancer
(Ardalan et al, 1991; Yeh and Cheng, 1994, 1997; Beerblock et al,
1997; de Gramont et al, 1998) and gastric cancer (Vanhoefer et al,
1994; Hsu et al, 1997; Cheng et al, 1998; Yeh and Cheng, 1998).
HDFL appeared to be effective in a substantial portion of patients
with advanced colorectal (Weh et al, 1994; Yeh et al, 1997), gastric
(Vanhoefer et al, 1994), and breast cancer (Wilke et al, 1996), who
had failed to response to or progressed after a conventional-
schedule 5-FU regimen. This study sought to further clarify the
underlying mechanisms that contribute to the enhanced efficacy of
HDFL through in vitro studies of the differential regulation of
thymidylate synthase (TS).
Thymidylate synthase (TS) is the target enzyme of 5-FU
(Tsujinaka et al, 1992; Peters et al, 1994). Overexpression of TS
has been demonstrated to be closely associated with drug-resis-
tance toward 5-FU-based chemotherapy in colorectal cancers
(Johnston et al, 1994; 1995) and gastric cancers (Johnston et al,
1995; Lenz et al, 1996; Yeh et al, 1998a).
5-FU has a short plasma half-life of approximately 8–14 min
(Grem et al, 1991). By 24-h infusion of 5-FU 1000–2000 mg m–2,
the concentration of 5-FU in the peripheral blood was maintained
for 24 h at around 5–10 µ M (Fraile et al, 1980; Grem, 1996).
However, by conventional bolus injection or short intravenous
infusion of 5-FU 370–500 mg m–2, the concentrations of 5-FU in
the peripheral blood was around 100–200 µ M, lasting for less than
1 h (Grem, 1996). Although direct evidence remains lacking, these
findings suggest that the extent of inhibition of free TS, one of the
main sources of 5-FU drug-resistance, may be different in these
two representative schedules of 5-FU. The results of this study
provide in vitro evidence that 24-h infusion of high-dose 5-FU
may result in a much more durable and effective suppression of TS
than conventional 5-FU regimens.
MATERIALS AND METHODS
Cell culture of human gastric cancer cells
The human gastric cancer cell line NCl-N87 (ATCC CRL-5822)
was obtained from the American Type Culture Collection (ATCC)
and maintained in RPMI 1640 cell culture medium (Life
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Technologies Inc, Rockville, MD, USA) containing 10% fetal
bovine serum (Life Technologies Inc).
Western blot analysis for determination of TS protein
expression
Total cellular protein from N87 cells was extracted by lysing
the cells at 4° C with lysis buffer containing 0.5% Nonidet P-40,
50 mM Tris (pH 7.4), 150 mM NaCl, 0.1% SDS, 100 mM NaF,
1 mM benzamidine, and 10 µ g ml–1 each of the following protease
inhibitors: trypsin inhibitor, aprotinin, and leupeptin. After
centrifugation at 14 000 rpm for 10 min at 4° C, protein concentra-
tions of the supernatants were determined with a Bio-Rad protein
assay reagent (Bio-Rad Laboratories, Hercules, CA, USA) by
checking absorbance at the wavelength of 595 nm. Forty micro-
grams of each protein sample was boiled at 95° C for 5 min, then
resolved by 12.5% SDS-polyacrylamide gel electrophoresis using
the method of Laemmli (1970).
The gels were electroblotted onto a nitrocellulose membrane,
incubated with blocking solution containing 5% (w/v) skimmed
milk in TBST (20 mM Tris HCl, 150 mM NaCl, 0.05% Tween 20,
pH 7.5) for 1 h, and then incubated with the TS106 monoclonal
antibody at 1:200 dilution (5 µ g ml–1) (Chemicon International
Inc, Temecula, CA, USA) at 4° C overnight.
After overnight incubation, the membrane was washed
thoroughly with TBST. A horseradish peroxidase-conjugated goat
anti-mouse immunoglobin was then added as the secondary anti-
body at 1:5000 dilution and incubated for 1 h at room temperature.
The membrane was washed again with TBST. The protein bands
were visualized by enhanced chemiluminescence assay reagents
(Amersham Pharmacia Biotech Inc, Piscataway, NJ, USA).
Northern blot analysis for determination of steady-state
mRNA of TS
Total cellular RNA was prepared by acid guanidinium thio-
cyanate-phenol-chloroform extraction using the method of
Chomczynski and Sacchi (1987). Briefly, the RNA extraction was
conducted with N87 cells treated with each protocol. Cells were
lysed directly by adding with 4 ml of the Ultraspec RNA extrac-
tion reagent (Biotecx Laboratories Inc, Houston, TX, USA) into
each dish. Cell lysate was transferred into polypropylene tubes,
and 0.8 ml of chloroform: isoamylalcohol mixture (24:1) was
added to accelerate the separation of the two layers after acid
phenol extraction (pH 4.0). The upper layer, which contains RNA,
was precipitated by isopropanol, and the RNA pellet was dissolved
in diethylpyrocarbonate-treated water.
RNA was separated by electrophoresis on 1.2%
agarose/formaldehyde gels in the presence of ethidium bromide,
and transferred to Hybond-N nylon membrane (Amersham
Pharmacia Biotech Inc). Blots were pre-hybridized for 2 h at 42° C
in 2% (w/v) blocking agent (Boehringer Mannheim Biochemicals,
Indianapolis, IN, USA), 50% deionized formamide, 5X SSC (1X
SSC containing 150 mM NaCl, 15 mM sodium citrate, pH7.0),
0.2% (w/v) SDS, 0.1% (w/v) N-lauroyl sarcosine, and 20 µ g ml–1
poly rC (Sigma Chemical Co, St. Louis, MO, USA). Hybridization
was conducted overnight under the same conditions at a probe
concentration of 2 × 106 dpm ml–1. Two probes were used in this
study. One is human thymidylate synthase (TS) cDNA fragment
(496 bp) and the other is human glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) cDNA fragment (790 bp). Both cDNA
fragments were prepared as described previously (Yeh et al,
1998b). The DNA probes were labelled with α -[32P]-dCTP using a
Rediprime labelling kit according to the manufacturers’ protocols
(Amersham Life Sciences, Arlington Heights, IL, USA). After
hybridization, blots were washed twice in 2  SSC-0.2% (w/v)
SDS at room temperature, and twice in 0.1  SSC-0.2% (w/v) SDS
at 68° C prior to autoradiography at –80° C.
Determination of TS expression with ‘30-min short
exposure’ vs ‘24-h prolonged exposure’ of 5-FU
Effects of 5-FU dose on TS expression
N87 cells were cultured by splitting and plating 5 × 106 cells per
10-cm culture dish for collection at 24 h after the start of 5-FU
treatment. After the cells were plated and cultured overnight, they
were treated by the two representative schedules which were
designed to mimic in vivo conditions which occur with conven-
tional bolus injection/short infusion regimens of 5-FU (30-min
short exposure) and HDFL regimens (24-h prolonged exposure).
The effects of 5-FU dose were tested with both schedules using a
series of concentrations of 5-FU. For 30-min short exposure, the 5-
FU doses used for treatment were 1 µ M, 5 µ M, 10 µ M, 50 µ M,
100 µ M, and 200 µ M. For 24-h prolonged exposure, the 5-FU
doses used for treatment were 0.1 µ M, 0.25 µ M, 0.5 µ M, 1 µ M,
2.5 µ M, 5 µ M, and 10 µ M. After 5-FU exposure for the indicated
time duration, the medium was removed and cells were washed
twice with 1  PBS, and fresh RPMI medium was then replaced.
The cells were then harvested at 24 h after the start of 5-FU
treatment, respectively.
Time-course effects of 5-FU on TS expression
N87 cells were cultured by splitting and plating 5 × 106 cells,
2.5 × 106 cells, and 1.25 × 106 cells per 10-cm culture dish for
collection at or before 24h, at 48 h, and at 72 h after the start of
5-FU treatment, respectively. The cells were treated with either
30-min short exposure of 5-FU at the concentration of 200 µ M, or
24-h prolonged exposure at the concentration of 5.0 µ M. After
5-FU exposure for the indicated time duration, the medium was
removed, and cells were washed twice with 1  PBS, and fresh
RPMI medium was then replaced. The cells were harvested at 1, 3,
6, 9, 12, 24, 48, and 72 h after the start of 5-FU treatment,
respectively.
MTT cytotoxicity assay of two modes of 5-FU treatment
The cytotoxicity effects of 5-FU with the two modes of adminis-
tration were evaluated by an MTT (3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl) tetrazolium bromide) assay. The growth curve of the
N87 cells was determined first in a 96-well culture plate with
various numbers of cells. Based on the growth curve, optimal
number of cells that would be expected to grow exponentially at
72, 96, and 120 h were plated into each well. The cells were
allowed to grow and stabilize overnight before 5-FU was added.
Subsequently, the cells were treated with 24-h prolonged expo-
sure to low-dose 5-FU or 30-min short exposure to high-dose 5-
FU with the series of concentrations of 5-FU described above.
Each treatment was performed in triplicate. After treatment, cells
were washed twice with 1  PBS, then 100 µ l fresh medium was
added. Cells were allowed to grow for a total of 72, 96, and 120 h
after the start of 5-FU treatment, respectively. At the end of
the indicated incubation period, the number of viable cells was1512 K-H Yeh et al
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determined by MTT assay. Fifty microliters of MTT reagent (2 mg
of MTT ml–1 medium) was added to each well followed by incuba-
tion at 37° C for 2.5 h. The plate was centrifuged at 2000 rpm for 5
min at 4° C. Medium was removed and 150 µ l of DMSO was
added to each well. The absorbance of each well was read by a
spectrophotometric plate-reader at the wavelength of 492 nm.
Cell cycle analysis by flowcytometry for the two modes
of 5-FU treatment
After completion of 5-FU treatment as described above, N87 cells
were trypsinized into single cells, washed once in RPMI, washed
once in 1X cold PBS, then fixed in 75% cold ethanol. Cells were
stained with 1 ml of propidium iodide solution (2.5 mg of
propidium iodide in 50 ml of 1  PBS), and the corresponding
cell-cycle status was analysed by FACScan (Becton Dickinson,
Mountain View, CA, USA) using the histograms of the program
Cell Quest (Becton Dickinson). A total of 10 000 cells were
counted by flowcytometry for each cell sample.
Statistics
The statistical significance of comparison of cell-cycle regulation
by the two modes of 5-FU treatment was analysed by the Student’s
t-test. A P value less than 0.05 was considered significant.
RESULTS
Effects of 5-FU dose on TS expression in the two
modes of 5-FU treatment
After 30-min short exposure to various concentrations of 5-FU,
N87 cells were harvested at 24 h after the start of 5-FU treatment,
and TS protein expression was determined by Western blot
analysis. As shown in Figure 1A, the expression of ternary
complex of TS (upper band) was increased in a dose-dependent
manner. However, free TS expression (lower band) remained the
same even at the highest 5-FU concentration of 200 µ M, which is
the estimated serum concentration achieved by bolus injection of a
conventional dose of 5-FU.
As shown in Figure 1B, after 24-h prolonged exposure to
various lower concentrations of 5-FU, the amount of ternary
complex of TS (upper band) was also increased in a dose-
dependent manner. In contrast to the high-concentration/
short-exposure mode, free TS (lower band) expression remained
significantly down-regulated at 24 h by 2.5–10 µ M concentrations
of 5-FU, which are the estimated serum concentrations achieved
by 24-h infusion of high-dose 5-FU.
For further analysis of the time-course effects, 30-min short
exposure to 200 µ M of 5-FU and 24-h prolonged exposure to 5
µ M of 5-FU were selected as the representative conditions for the
following experiments.
Time-course effects of 5-FU on TS expression
As shown in Figure 2A, after 30-min short exposure to 200 µ M of
5-FU, the ternary complex of TS (upper band) gradually accumu-
lated up to 24 h, and decreased thereafter. The free TS expression
(lower band) was depleted immediately after exposure to 5-FU,
but started to recover at 3 h. Complete recovery of free TS was
noted at 12 h after the start of 5-FU treatment. In contrast, as
shown in Figure 2B, after 24-h prolonged exposure to 5 µ M of
5-FU, the ternary complex of TS (upper band) continued to accu-
mulate up to 72 h, and the free TS (lower band) was still depleted
at 24–48 h.
Effects of 5-FU dose on steady-state mRNA of TS
Northern blot analysis showed that steady-state mRNA of TS was
not significantly affected by either of the 5-FU treatment
schedules, as shown in Figure 3.
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Figure 1 Effects of 5-FU dose on TS protein expression in the two
representative modes of 5-FU treatment. (A) After 30-min short exposure of
N87 cells to 5-FU (0, 1, 5, 10, 50, 100, and 200 µ M), Western blot analysis to
determine TS protein expression was performed at 24 h after the start of
5-FU treatment. β -Actin was used as internal control for protein expression.
(B) After 24-h prolonged exposure of N87 cells to 5-FU (0, 0.1, 0.25, 0.5, 1,
2.5, 5, and 10 µ M), Western blot analysis of TS protein expression was
performed at 24 h after the start of 5-FU treatment. The lower band denotes
the free form of active TS, and the upper band denotes the ternary complex
of inactive TS. β -Actin was used as internal control for protein expression
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Figure 2 Time-course effects of 5-FU on TS protein expression. (A) After
30-min short exposure of N87 cells to 200 µ M of 5-FU, Western blot analysis
of TS protein expression was performed at 1, 3, 6, 9, 12, 24, 48, and 72 h
after the start of 5-FU treatment. β -Actin was used as internal control for
protein expression. (B) After 24-h prolonged exposure of N87 cells to 5 µ M of
5-FU, Western blot analysis of TS protein expression was performed at 1, 3,
6, 9, 12, 24, 48, and 72 h after the start of 5-FU treatment. β -Actin was used
as internal control for protein expressionTS suppression by high-dose 5-FU infusion 1513
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Comparison of cytotoxicity for the two modes of 5-FU
treatment
The dose-response curves after 72, 96, and 120 h of cell culture are
shown in Figures 4A, 4B and 4C, respectively. The 24-h-exposure
mode consistently suppressed cell growth up to 120 h, with an IC50
of around 5–10 µ M. In contrast, the 30-min-exposure mode had a
shorter duration of growth suppression, as evidenced by the
regrowth of cells at 120 h. Further, the IC50 was more than 200 µ M
at 72 and 96 h with the 30-min-exposure mode.
Comparison of cell-cycle regulation by the two modes
of 5-FU treatment
As shown in Figure 5, 24-h prolonged exposure to 2.5–5 µ M of 5-
FU resulted in significantly greater S-phase blockade than 30-min
short exposure to 200–400 µ M of 5-FU (24-h exposure to 5 µ M vs
30-min exposure to 200 µ M of 5-FU, P = 0.005, t-test). The
G0/G1 and G2/M fractions were also more suppressed by the low-
dose/prolonged exposure mode.
DISCUSSION
Recently, evidence has accumulated that a weekly 24-h infusion of
high-dose 5-FU may improve the response rate and survival time
compared with 5-FU bolus regimens (Meta-analysis Group in
Cancer, 1998). In a randomized multicentre trial for metastatic
colorectal cancer, Kohne et al (1998) reported an overall response
rate of 44% and a median survival time of 16 months using a
weekly-times-six schedule of infusional 5-FU (2600 mg m–2 24-h
infusion) (Kohne et al, 1998). In another randomized study for
advanced colorectal cancer, de Gramont et al (1997) reported a
significantly better outcome in patients treated by a similar
schedule which combined ‘bolus plus infusional’ 5-FU compared
to ‘bolus’ 5-FU (de Gramont et al, 1997). These results suggest
that 24- or 48-h infusion of high-dose 5-FU is more effective than
the conventional bolus schedules. However, the pharmacodynamic
mechanism responsible for this improved effect is not clear. In this
in vitro study, we have demonstrated that a 24-h-infusional 5-FU
schedule provides significantly better suppression of TS than the
conventional bolus 5-FU schedule.
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Figure 3 Effects of 5-FU dose on steady-state mRNA of TS. (A) After
30-min short exposure of N87 cells to 5-FU (0, 1, 5, 10, 50, 100, and
200 µ M), Northern blot analysis for steady-state mRNA of TS was performed
at 24 h after the start of 5-FU treatment. GAPDH was used as internal control
for mRNA expression. (B) After 24-h prolonged exposure of N87 cells to
5-FU (0, 0.1, 0.25, 0.5, 1, 2.5, 5, and 10 µ M), Northern blot analysis for
steady-state mRNA of TS was performed at 24 h after the start of 5-FU
treatment. GAPDH was used as internal control for mRNA expression
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Figure 4 Comparison of cytotoxicity of the two modes of 5-FU treatment.
Y-axis denotes survival fractions (%, mean ± standard deviation) of NCl-N87
gastric cancer cells. X-axis denotes a series of 5-FU concentrations (µ M).
Results using the two representative modes of 5-FU treatment are shown.
(A) MTT assay at 72 h after the start of 5-FU treatment. (B) MTT assay at 96
h after the start of 5-FU treatment. (C) MTT assay at 120 h after the start of
5-FU treatment
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Figure 5 Comparison of cell-cycle regulation by the two modes of 5-FU
treatment. Y-axis denotes the G0/G1, S, and G2/M phases of cell cycle,
respectively (%, mean ± standard deviation). X-axis: C = control, no 5-FU
treatment; 1 = 24-h treatment with 2.5 µ M of 5-FU; 2 = 24-h treatment with
5.0 µ M of 5-FU; 3 = 30-min treatment with 200 µ M of 5-FU; and 4 = 30-min
treatment with 400 µ M of 5-FU. Cells were collected for flowcytometric
analysis at 24 h after the start of 5-FU treatment1514 K-H Yeh et al
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The monoclonal antibody, TS106, detects two bands of
thymidylate synthase (Johnston et al, 1991). The upper band was
not apparent in cells that had not been exposed to 5-FU. However,
only the upper band was detected in cells incubated with excess
5-fluorodeoxyuridine monophosphate (FdUMP) or 5, 10-methyl-
ene-tetrahydrofolate (CH2H4PteGlu), suggesting that the upper
band represents the ternary complex of TS while the lower band
represents the free form of TS protein (Johnston et al, 1991). The
free form of TS is an active enzyme and its expression is inversely
correlated with the drug sensitivity of several human cancers (Chu
et al, 1991a; Li et al, 1995). The ternary complex is an inactive
form of TS and its activity has been shown to be inhibited by
complexing with FdUMP (Johnston et al, 1991; 1992; Grem,
1996). The results of this study indicate that 24-h prolonged expo-
sure to 5–10 µ M of 5-FU resulted in more sustained suppression of
free TS than 30-min short exposure to 100–200 µ M of 5-FU. With
the 24-h exposure, suppression of free TS was still evident more
than 24 h after the start of 5-FU treatment; however, with the
30-min exposure, suppression of free TS lasted for less than 12 h.
The mechanism responsible for the prolonged suppression of TS
by the 24-h-infusional schedule remains unclear. TS expression
has been reported to be regulated at both a transcriptional (Dolnick
et al, 1996; Banerjee et al, 1998) and a translational level (Chu et
al, 1991b; Chu and Allegra, 1996). In this study, the steady-state
expression of the mRNA of TS was not affected by either of the
5-FU treatment schedules. Therefore, translational regulation of
TS may have played an important role in prolonged suppression of
TS with the 24-h-infusional schedule. In a model of translational
regulation of the expression of TS, excess free TS would bind to
the regulatory region of TS mRNA, and causes feedback inhibition
of TS translation (Chu et al, 1991b; Chu and Allegra, 1996). The
formation of the ternary complex releases free TS from the regula-
tory region of mRNA, and therefore results in a rebound of TS
translation (Chu et al, 1991b; Chu and Allegra, 1996). This model
appears to helpfully explain the observations of this study. In the
short-exposure mode, free TS was completely depleted during the
first hour of exposure to high-dose 5-FU. The absence of free TS
then caused increased TS translation, which became apparent at 3
h, and even overshot to a level higher than the control at 24 h after
the start of 5-FU treatment. In the prolonged-exposure mode, the
new TS synthesized as a result of increased TS translation was
very likely depleted by the continual formation of the ternary
complex. Higher TS activity, representing an increased amount of
free TS, was noted during the S-phase under physiological condi-
tions (Navelgund et al, 1980). Since 24-h prolonged infusion with
5–10 µ M of 5-FU resulted in enhanced suppression of free TS, it
thus caused more S-phase blockade and enhanced cytotoxicity, as
was found in this study.
The optimal dose and schedule of infusional 5-FU remains
unclear. The data of the present study suggest that a concentration
of 2.5 µ M, a level less than half of that achieved by 24-h infusion
of 2600 mg m–2 of 5-FU still effectively suppressed free TS
(Figure 1B). Our results also suggest that exposure of cancer cells
to 2.5 µ M of 5-FU for more than 24 h may result in even higher
cytotoxicity (data not shown). The results of the bimonthly 48-h
infusional protocol used by de Gramont et al seem to support this
suggestion (Beerblock et al, 1997; de Gramont et al, 1997; 1998).
These findings may form the bases for further exploration of the
optimal dose/schedule for infusional 5-FU treatment.
We conclude that 24-h exposure of gastric cancer cells to
low-concentration of 5-FU, as compared with 30-min exposure to
high-concentration of 5-FU, resulted in better suppression of free
TS, higher degree of S-phase blockade, and enhanced cytotoxicity.
The findings of these in vitro studies may help explain the
improved clinical efficacy of HDFL regimens.
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